Clinical Scorecard: Impact of Pyridoxamine, an AGE Inhibitor, on Bone Health in Elderly Women with Type 2 Diabetes: Results from a Randomized Clinical Trial
At a Glance
Category
Detail
Condition
Type 2 diabetes-associated bone fragility with reduced bone turnover and increased fracture risk
Key Mechanisms
Inhibition of advanced glycation end products (AGEs) formation by pyridoxamine to improve bone formation
Target Population
Older women (≥65 years) with type 2 diabetes
Care Setting
Academic clinical research center
Key Highlights
Pyridoxamine (200 mg twice daily) increased bone formation marker P1NP by 23% over 1 year compared to placebo.
Femoral neck bone mineral density increased significantly with pyridoxamine treatment versus placebo.
Pyridoxamine reduced HbA1c levels and bone fluorescent AGEs correlated strongly with skin autofluorescence.
Guideline-Based Recommendations
Diagnosis
Assess bone turnover markers such as P1NP in older women with T2D to evaluate bone formation status.
Use skin autofluorescence as a noninvasive correlate of bone AGE accumulation.
Management
Consider pyridoxamine as a potential disease mechanism–directed therapy to increase bone formation and BMD in older women with T2D.
Maintain vitamin D sufficiency (25(OH)D ≥ 50 nmol/L) prior to intervention.
Monitor and optimize glycemic control as HbA1c reduction correlates with improved bone formation.
Monitoring & Follow-up
Monitor bone formation markers (P1NP) and bone mineral density during treatment.
Track HbA1c levels to assess metabolic response.
Observe for adverse events, which were similar between pyridoxamine and placebo groups.
Risks
No significant difference in adverse events between pyridoxamine and placebo groups was observed in the study.
Patient & Prescribing Data
Older women with type 2 diabetes at risk for bone fragility and fractures
Pyridoxamine at 200 mg twice daily for 1 year may improve bone formation and density while reducing HbA1c, with a safety profile comparable to placebo.
Clinical Best Practices
Screen for vitamin D deficiency and correct prior to initiating pyridoxamine therapy.
Use randomized, double-blind controlled trial data to guide pyridoxamine dosing and duration.
Stratify patients by ethnicity and SGLT2 inhibitor use due to potential differences in bone turnover and BMD.
Consider bone biopsy or skin autofluorescence measurements for research or complex cases to assess AGE burden.
by Aiden V Brossfield, Donald J McMahon, Jason Fernando, Beatriz Omeragic, Rukshana Majeed, Sanchita Agarwal, Grazyna E Sroga, Bowen Wang, Deepak Vashishth, Mishaela R Rubin
US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.
